Hepatitis B vaccination in patients with inflammatory bowel disease

Table 1 Demographics of the study population n

Characteristics	CD (n =292)	UC (n = 206)	IC (n = 2)
Age (yr, mean ± SD)	41.94 ± 16.3	43.2 ± 16.6	46.5 ± 37.5
Sex (Male/Female)	110/182	85/121	0/2
Race
African American	66 (22%)	37 (18%)	0 (0%)
Asian	3 (1%)	2 (1%)	0 (0%)
Native American	2 (0.7%)	1 (0.5%)	0 (0%)
White	200 (68%)	148 (72%)	2 (100%)
Ethnicity
Hispanic	14 (4.8%)	16 (8%)	0 (0%)
Not hispanic	278 (95%)	190 (92%)	2 (100%)
Immunosuppressants	187 (64%)	109 (53%)	2 (100%)
IBD disease duration
(mo, mean ± SD)	154 ± 138	107 ± 106	4 ± 4

UC: Ulcerative colitis; CD: Crohn’s disease; IC: Indeterminate colitis.

Table 2 Prevalence of hepatitis B virus markers in subjects who have serology data available n (%)

Disease Type	HBsAg	Anti-HBc Ab
Crohn’s disease (n = 143)	4 (2.8)	6 (4.2)
Ulcerative colitis (n = 76)	0 (0)	1 (1.3)
Indeterminate colitis (n = 1)	0 (0)	0 (0)
Total (n = 220)	4 (1.8)	7 (3.2)

HBsAg: Hepatitis B surface antigen; anti-HBc Ab: Hepatitis B core antibodies.

Table 3 Characteristics of the 7 hepatitis B virus - positive patients

Patients	Age (yr)	Sex	Ethnicity	IBD	Immunosupression	Serology	Viral Load (copies/mL)	HBV states
1	54	Male	White	CD	Adalimumab	HBsAg+	135039	Chronic infection
					Azathioprine	Anti-HBs Ab-
						HBeAg+
						Anti-HBe Ab-
						Anti-HBc Ab+
2	56	Female	African american	CD	-	HBsAg+	244	Chronic infection
						Anti-HBs Ab-
						Anti-HBc Ab+
						HBeAg-
3	56	Female	White	CD	-	HBsAg+	121	Chronic infection
						Anti-HBs Ab-
						Anti-HBc Ab+
						HBeAg-
4	61	Male	African american	CD	-	HBsAg+	1000000	Chronic infection
						Anti-HBs Ab-
						HBeAg+
						Anti-HBe Ab-
						Anti-HBc Ab+
5	54	Female	African american	CD	Adalimumab	HBsAg-	< 10	Past infection,
						Anti-HBs Ab+		Naturally immune
						Anti-HBc Ab+
6	62	Female	African american	UC	-	HBsAg-	-	Past infection,
						Anti-HBs Ab+		Naturally immune
						Anti-HBc Ab+
7	64	Female	African american	CD	Prednisolone	HBsAg-	-	Past infection,
						Anti-HBs Ab+		Naturally immune
						Anti-HBc Ab+

UC: Ulcerative colitis; CD: Crohn’s disease; IBD: Inflammatory bowel disease; HBsAg: Hepatitis B surface antigen; anti-HBc Ab: Hepatitis B core antibodies.

Table 4 Prevalence of hepatitis B virus in our inflammatory bowel disease study vs in European studies

	Loras 2009 (study 1)	Chevaux 2010 (study 2)	Our IBD study	Study 1 vs our study(P value)	Study 2 vs our study(P value)
Chronic HBV (HBsAg)	0.7%	0.95%	1.8%	0.070	0.159
Exposure to HBV (Anti-HBc Ab)	7.5%	2.50%	3.2%	0.006	0.313

IBD: Inflammatory bowel disease; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; anti-HBc Ab: Hepatitis B core antibodies.